Study in End Stage Renal Disease (ESRD) Patients on Hemodialysis Comparing the Theranova Dialyzer to Hemodiafiltration

NACompletedINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

June 29, 2018

Primary Completion Date

January 4, 2020

Study Completion Date

January 4, 2020

Conditions
End Stage Renal Disease
Interventions
DEVICE

Theranova 400 Dialyzer

Dialysis performed in HD mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.

DEVICE

FX800 Dialyzer

Dialysis performed in HDF mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.

Trial Locations (8)

100034

Investigational Site, Beijing

200011

Investigational Site, Shanghai

230601

Investigational Site, Hefei

310014

Investigational Site, Hangzhou

430060

Investigational Site, Wuhan

450052

Investigational Site, Zhengzhou

510515

Investigational Site, Guangzhou

610041

Investigational Site, Chengdu

All Listed Sponsors
collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Vantive Health LLC

INDUSTRY

NCT03547336 - Study in End Stage Renal Disease (ESRD) Patients on Hemodialysis Comparing the Theranova Dialyzer to Hemodiafiltration | Biotech Hunter | Biotech Hunter